Home > Insider Trading > Filing (0001179110-11-004052)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157601	Synta Pharmaceuticals Corp	SNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1325718	Keizo Koya	C/O Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington MA 02421	Sr. Vp, Drug Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-03-01	18,270	$5.23	32,999	No	4	S	Direct
Common Stock	Acquisiton	2011-03-01	6,844	$0.00	39,843	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2011-03-01	58,200	$0.00	58,200	$5.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
58,200		2021-03-01	No	4	A	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2010, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2010.
The shares were sold in multiple transactions at prices ranging from $5.20 to $5.31 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 100% of the shares on March 1, 2012, provided the Reporting Person remains employed by the Issuer on such date.
The option vests as to 25% of the shares on March 1, 2012 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.